52629-26-2

Basic information

• Product Name: Propanoic acid, 2-methyl-3-oxo-3-(phenylamino)-, ethyl ester
• Synonyms: Isobernsteinsaeure-aethylester-anilid;2-Methyl-N-phenyl-malonamidsaeure-aethylester;Ethyl 2-methyl-3-oxo-3-(phenylamino)propanoate;Methylmalonsaeure-aethylester-anilid;2-methyl-N-phenyl-malonamic acid ethyl ester
• CAS NO: 52629-26-2
• Molecular Formula: C12H15NO3
• Molecular Weight: 221.256
• Mol File: 52629-26-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Propanoic acid, 2-methyl-3-oxo-3-(phenylamino)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 2-methyl-3-oxo-3-(phenylamino)-, ethyl ester(52629-26-2)
• EPA Substance Registry System: Propanoic acid, 2-methyl-3-oxo-3-(phenylamino)-, ethyl ester(52629-26-2)

Safety Data

• Hazardous Substances Data: 52629-26-2(Hazardous Substances Data)

Upstream product

• 62-53-3 aniline 
• 609-08-5 Diethyl methylmalonate 
• 34757-17-0 ethyl 2,2-dibromopropanoate 
• 103-71-9 phenyl isocyanate 
• 4504-12-5 ethyl 5-oxo-2-phenyl-2,5-dihydroisoxazole-4-carboxaldehyde 
• 74-88-4 methyl iodide 
• 2009-97-4 ethyl 2-diazo-3-oxobutanoate 
• 50496-34-9 ethyl 2-chloroformylpropanoate 
• 2985-33-3 monoethyl methylmalonate 

Downstream Products

• 1873-59-2 4-hydroxy-3-methyl-2-quinolone 
• 15601-92-0 2-methyl-3-oxo-3-(phenylamino)propanoic acid 
• 120-72-9 indole 

Relevant articles and documents

One-step Synthesis of 3-Unsubstituted 4-Hydroxy-2(1H)-Quinoline

3-Unsubstituted 4-hydroxy-2(1H)-quinolone (DHQ) derivatives were synthesized from aniline derivatives and diethyl malonate at low temperature using AlCl3 as catalyst and Eaton reagent as acidic environment. A reaction mechanism was proposed and elucidated. Different synthetic intermediates are specially prepared or purified and used to understand the reaction and validation mechanism.

4-Hydroxy-3-methyl-2(1h)-quinolone, originally discovered from a brassicaceae plant, produced by a soil bacterium of the genus burkholderia sp.: Determination of a preferred tautomer and antioxidant activity

4-Hydroxy-3-methyl-2(1H)-quinolone (1), a molecule known for a long time and recently discovered from a Brassicaceae plant Isatis tinctoria without providing sufficient evidence to support the structure, was isolated from a fermentation extract of Burkholderia sp. 3Y-MMP isolated from a soil by a Zn2+ enrichment culture. Detailed spectroscopic analyses by MS and NMR, combined with 13C chemical shift comparison with literature values of the related compounds and a synthetic preparation of 1, allowed its first full NMR characterization and identification of 2-quinolone but not 2-quinolinol (2) as the preferred tautomer for this heterocyclic system. While the metal-chelating activity was negligible, compound 1 at 10 μM, a concentration lower than that in liquid production cultures, quenched hydroxy radical-induced chemiluminescence emitted by luminol by 86percent. Because some Burkholderia species are pathogenic to plants and animals, the above result suggests that 1 is a potential antioxidant to counteract reactive oxygen species-based immune response in the host organisms.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.